Navigation Links
Neuropathy Patients More Likely to Receive High-cost, Low-yield Screening Instead of More Effective Tests
Date:1/23/2012

ANN ARBOR, Mich., Jan. 23, 2012 /PRNewswire-USNewswire/ -- Researchers at the University of Michigan analyzed the tremendous cost of diagnosing peripheral neuropathy and found that less expensive, more effective tests are less likely to be used.

Almost one-quarter of patients receiving neuropathy diagnoses undergo high-cost, low-yield MRIs while very few receive low-cost, high-yield glucose tolerance tests, according to the study that will be published Jan. 23 in the Archives of Internal Medicine.

The research was led by Brian Callaghan, M.D., assistant professor of neurology at the University of Michigan Medical School.

Patients diagnosed with peripheral neuropathy typically are given many tests but physicians are highly variable in their approach, says Callaghan.

"We spend a lot of money to work up a diagnosis of neuropathy. The question is whether that money is well spent," Callaghan says.

For patients with peripheral neuropathy, the nerves that carry information to and from the brain don't work property. This commonly leads to tingling or burning in arms or legs and loss of feeling — and the symptoms can go from subtle to severe.

Diabetes is the most common cause of this type of nerve problem. Peripheral neuropathy is found in about 15 percent of those over age 40.

Researchers used the 1996-2007 Health and Retirement Study to identify individuals with a diagnosis of peripheral neuropathy. They focused on 15 relevant tests and examined the number and patterns of tests six months before and after the initial diagnosis.

"Our findings, that MRIs were frequently ordered by physicians, but a lower-cost glucose tolerance test was rarely ordered, show that there is substantial opportunity to improve efficiency in the evaluation of peripheral neuropathy," Callaghan says.

"Currently no standard approach to the evaluation of peripheral neuropathy exists. We need more research to determine an optimal approach.

"We do a lot of tests that cost a lot of money, and there's no agreement on what we're doing."

The climbing rates of diabetes in the U.S. make this research even more important, says co-author Kenneth M. Langa, M.D., Ph.D., a professor of Internal Medicine at U-M, a Research Scientist at the VA Ann Arbor Healthcare System's Center for Clinical Management Research, and Research Professor at the Institute for Social Research.

"We know more and more people may develop peripheral neuropathy because it is commonly caused by diabetes. Our study suggests that the work-up currently used for neuropathy isn't standardized and tests that are less useful and more expensive may be used too often," says Langa. "We need a more efficient way to handle this increasingly common diagnosis."

Journal reference: Arch Intern Med. 2012; 172[2]:127-132.

Funding: National Institutes of Health, Katherine Rayner Program and A. Alfred Taubman Medical Research Institute. The Health and Retirement Study is supported by the National Institute on Aging.

Additional authors: Ryan McCammon, Kevin Kerber, M.D., Xiao Xu, Ph.D., and Eva Feldman, M.D., Ph.D.; all of the University of Michigan.

About the University of Michigan's Department of Neurology: The department is an academic medical department with a full range of activities in patient care, education and research. The Neurology inpatient service provides care for acutely ill patients with neurologic disease and includes a dedicated intensive care unit, a separate stroke unit, and inpatient epilepsy monitoring beds. Our faculty also investigate the causes, treatments, natural history and phenotypic spectrum of inherited neurologic disorders, such as Alzheimer's disease. Our studies range from describing novel inherited neurologic syndromes; to family studies including genetic mapping; discovering genes for neurologic diseases; and the creation and analysis of laboratory animals of neurologic disease.


'/>"/>
SOURCE University of Michigan Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
7. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
8. Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy, According to HealthCore Study Presented at ISPOR
9. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
10. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
11. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
Breaking Medicine News(10 mins):